Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Hydrochloric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA known ✓ | P10253 | 1/20 | 0.56 |
| ▸ | HSF1 | Q00613 | 13/20 | 0.57 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.56 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.47 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.47 |
| ▸ | TSHR | P16473 | 1/20 | 0.45 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.45 |
| ▸ | ATM | Q13315 | 1/20 | 0.45 |
| ▸ | ACE2 | Q9BYF1 | 1/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL3068294 | 1.00 | HSF1 (0.57) | HSF1ALDH1A1GAACYP2D6CYP2C19 | |
| Hydrochloric Acid SCHEMBL3074000 | 0.86 | ALDH1A1 (0.59) | HSF1ALDH1A1GAACYP2D6CYP2C19 | |
| Hydrochloric Acid SCHEMBL3059709 | 0.86 | ALDH1A1 (0.59) | HSF1ALDH1A1GAACYP2D6CYP2C19 | |
| Hydrochloric Acid SCHEMBL3076169 | 0.81 | HSF1 (0.64) | HSF1CYP2D6CYP2C19TSHRHIF1A | |
| Hydrochloric Acid SCHEMBL3076170 | 0.81 | HSF1 (0.64) | HSF1CYP2D6CYP2C19TSHRHIF1A | |
| SCHEMBL6009203 | 0.79 | HSF1 (0.65) | HSF1CYP2D6TSHRHIF1AKDM4E | |
| SCHEMBL6009202 | 0.79 | HSF1 (0.65) | HSF1CYP2D6TSHRHIF1AKDM4E | |
| SCHEMBL8790783 | 0.79 | HSF1 (0.54) | HSF1ALDH1A1GAACYP2D6CYP2C19 | |
| Hydrochloric Acid SCHEMBL7883817 | 0.79 | HSF1 (0.54) | HSF1CYP2D6CYP2C19TSHRHIF1A | |
| Hydrochloric Acid SCHEMBL7541858 | 0.79 | HRH3 (0.48) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0966283-B1 | PHARMACEUTICAL PRODUCTS FOR CURING AND PREVENTING DISEASES RESULTING FROM THE DAMAGING OF THE VASCULAR ENDOTHELIAL CELLS | CYTRX CORP (US) | 2006-06-14 | — | — | EP | claimed |
| US-6143741-A | TREATING OR PREVENTING ILLNESSES RESULTING FROM DAMAGED ENDOTHELIAL CELLS SUCH AS ATHEROSCLEROSIS, THROMBOSIS, RESTENOSIS, VESSEL SPASM BY ADMINISTERING HYDROXYLAMINE DERIVATIVE | BIOREX Kutato es Fejleszo Rt. (HU) | 2000-11-07 | — | — | US | claimed |
| EP-0966283-A2 | PHARMACEUTICAL PRODUCTS FOR CURING AND PREVENTING ILLNESSES CONNECTED WITH THE MALFUNCTION OF VASCULAR ENDOTHELIAL CELLS | BIOREX RT. (HU) | 1999-12-29 | — | — | EP | claimed |
| WO-1998006400-A2 | PHARMACEUTICAL PRODUCTS FOR CURING AND PREVENTING ILLNESSES CONNECTED WITH THE MALFUNCTION OF VASCULAR ENDOTHELIAL CELLS | BIOREX KUTATÓ ÉS FEJLESZTO^' RT. (HU) | 1998-02-19 | — | — | WO | claimed |
| US-20100267711-A1 | METHOD OF ENHANCING CELLULAR PRODUCTION OF MOLECULAR CHAPERONE, HYDROXYLAMINE DERIVATIVES USEFUL FOR ENHANCING THE CHAPERONE PRODUCTION AND THE PREPARATION THEREOF | CYTRX CORPORATION (US) | 2010-10-21 | — | — | US | disclosed |
| US-7745465-B2 | Method of enhancing cellular production of molecular chaperone, hydroxylamine derivatives useful for enhancing the chaperone production and the preparation thereof | CYTRX CORPORATION (US) | 2010-06-29 | — | — | US | disclosed |
| US-7148239-B2 | Method of enhancing cellular production of molecular chaperon, hydroxylamine derivatives useful for enhancing the chaperon production and the preparation thereof | CYTRX CORPORATION (US) | 2006-12-12 | — | — | US | disclosed |
| EP-0966283-B1 | PHARMACEUTICAL PRODUCTS FOR CURING AND PREVENTING DISEASES RESULTING FROM THE DAMAGING OF THE VASCULAR ENDOTHELIAL CELLS | CYTRX CORP (US) | 2006-06-14 | — | — | EP | disclosed |
| US-20040067940-A1 | Method of enhancing cellular production of molecular chaperon, hydroxylamine derivatives useful for enhancing the chaperon production and the preparation thereof | BIOREX RESEARCH & DEVELOPMENT CO. | 2004-04-08 | — | — | US | disclosed |
| US-20040019103-A1 | Method of enhancing cellular production of molecular chaperon, hydroxylamine derivatives useful for enhancing the chaperon production and the preparation thereof | BIOREX RESEARCH & DEVELOPMENT CO. | 2004-01-29 | — | — | US | disclosed |
| US-6653326-B1 | For example, N-(2-hydroxy-3-(1-piperidinyl)propoxy)-3-pyridinecarboximidoyl chloride maleate; inducing gene expression of an eukaryotic cell under physiological stress; antiallergens; autoimmune diseases; cardiovascular disorders | BIOREX RESEARCH & DEVELOPMENT CO. (HU) | 2003-11-25 | — | — | US | disclosed |
| WO-2003045387-A1 | PHARMACEUTICAL COMPOSITION WITH COMBINED ACTIVE AGENTS CONTAINING METFORMIN AND A HYDROXYLAMINE DERIVATIVE | BIOREX KUTATÓ ÉS FEJLESZTÖ RT. (HU) | 2003-06-05 | — | — | WO | disclosed |
| US-6180787-B1 | Process for preparing o-(3-amino-2-hydroxy-propyl)-hydroxymic acid halides | BIOREX KUTATO ES FEJLESZTO RT. (HU) | 2001-01-30 | — | — | US | disclosed |
| US-6143741-A | TREATING OR PREVENTING ILLNESSES RESULTING FROM DAMAGED ENDOTHELIAL CELLS SUCH AS ATHEROSCLEROSIS, THROMBOSIS, RESTENOSIS, VESSEL SPASM BY ADMINISTERING HYDROXYLAMINE DERIVATIVE | BIOREX Kutato es Fejleszo Rt. (HU) | 2000-11-07 | — | — | US | disclosed |
| EP-0975585-A1 | PROCESS FOR PREPARING O-(3-AMINO-2-HYDROXY-PROPYL)-HYDROXYMIC ACID HALIDES | BIOREX KUTATO ES FEJLESZTÖ RT. (HU) | 2000-02-02 | — | — | EP | disclosed |
| EP-0966283-A2 | PHARMACEUTICAL PRODUCTS FOR CURING AND PREVENTING ILLNESSES CONNECTED WITH THE MALFUNCTION OF VASCULAR ENDOTHELIAL CELLS | BIOREX RT. (HU) | 1999-12-29 | — | — | EP | disclosed |
| WO-1998043948-A1 | PROCESS FOR PREPARING O-(3-AMINO-2-HYDROXY-PROPYL)-HYDROXYMIC ACID HALIDES | BIOREX KUTATÓ ÉS FEJLESZTO^' RT. (HU) | 1998-10-08 | — | — | WO | disclosed |
| WO-1998006400-A2 | PHARMACEUTICAL PRODUCTS FOR CURING AND PREVENTING ILLNESSES CONNECTED WITH THE MALFUNCTION OF VASCULAR ENDOTHELIAL CELLS | BIOREX KUTATÓ ÉS FEJLESZTO^' RT. (HU) | 1998-02-19 | — | — | WO | disclosed |
| EP-0801649-A2 | HYDROXYLAMINE DERIVATIVES USEFUL FOR ENHANCING THE MOLECULAR CHAPERON PRODUCTION AND THE PREPARATION THEREOF | BIOREX KUTATO ES FEJLESZTÖ RT. (HU) | 1997-10-22 | — | — | EP | disclosed |
| WO-1997016439-A1 | HYDROXYLAMINE DERIVATIVES USEFUL FOR ENHANCING THE MOLECULAR CHAPERON PRODUCTION AND THE PREPARATION THEREOF | Biorex Kutató és Fejlesztó Rt. (HU) | 1997-05-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100267711-A1 | METHOD OF ENHANCING CELLULAR PRODUCTION OF MOLECULAR CHAPERONE, HYDROXYLAMINE DERIVATIVES USEFUL FOR ENHANCING THE CHAPERONE PRODUCTION AND THE PREPARATION THEREOF | HSPE1, HSF1, HSP90AB2P | GAA 380/4885HSF1 2/4885ALDH1A1 533/4885 |
| US-20040019103-A1 | Method of enhancing cellular production of molecular chaperon, hydroxylamine derivatives useful for enhancing the chaperon production and the preparation thereof | HSPE1, HSF1, HSPA1A | GAA 544/4885HSF1 2/4885ALDH1A1 641/4885 |
| US-20040067940-A1 | Method of enhancing cellular production of molecular chaperon, hydroxylamine derivatives useful for enhancing the chaperon production and the preparation thereof | HSPE1, HSF1, HSPA1A | GAA 544/4885HSF1 2/4885ALDH1A1 641/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.